Biotechnology
BioDlink's Bevacizumab Approved for Market Launch in Indonesia, Marking Fourth Consecutive Emerging Market Authorization
* Bevacizumab Injection officially approved by Indonesia's National Agency of Drug and Food Control (BPOM), following Nigeria, Pakistan, and Colombia – accelerating global commercialization * Approval in ASEAN's largest pharma market strengthens BioDlink's position as a global supplier of ant...
2025-08-21 20:00
2414
SK bioscience Discusses Further Collaboration with the Gates Foundation to Advance Global Health
* Company holds a dedicated meeting with Gates Foundation executives during Bill Gates' visit to Korea. * Both reviews expanded cooperation, including next-generation preventive medicines. SEONGNAM, South Korea, Aug. 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biot...
2025-08-21 20:00
2832
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results
Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy Conference Calls Scheduled: Eng...
2025-08-21 18:02
4827
SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM
Now in its fourth year, the programme continues to empower biotech startups through ecosystem support and collaboration to advance science that serves patients. SINGAPORE, Aug. 21, 2025 /PRNewswire/ -- Singzyme, a Singapore-based biotech startup pioneering next-generation bioconjugation solution...
2025-08-21 17:38
1937
GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal
YONGIN, South Korea, Aug. 21, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based inSouth Korea, announced today that it has revealed the delivery mechanism of Hunterase (idursulfase beta), a recombinant enzyme replacement therapy for Hunter syndrome (MPS II). The res...
2025-08-21 13:00
1909
Debut of new form of health supplement product! WCC biomedical collaborate with Synmosa toward the niche market!
TAIPEI, Aug. 21, 2025 /PRNewswire/ -- WCC Biomedical
2025-08-21 09:23
1822
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results[1] Group performan...
2025-08-21 08:23
2954
Cell therapy is promising in treating psychiatric disorders, such as depression. -- A proof-of-principle study published in "Cell Stem Cell" by the laboratory of Dr. Chen, founder of UniXell Biotech, suggests this.
SHANGHAI, Aug. 20, 2025 /PRNewswire/ -- On August 11, 2025, the research team led by Professor Yuejun Chen, founder of UniXell Biotech, published an article titled "Human stem cell-derived A10 dopaminergic neurons specifically integrate into mouse circuits and improve depression-like behaviors" i...
2025-08-20 20:49
2508
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA
SHANGHAI, Aug. 19, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received INDclearance from the U.S. Food and Drug Administration (FDA). The clearance enables ...
2025-08-19 22:00
1946
WuXi Biologics Reports Solid 2025 Interim Results
* Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% * IFRS Gross profit margin expanded by 3.6% YoY to 42.7% * EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY * Adjusted EBITDA grew 20.6% YoY and adjusted net profit incr...
2025-08-19 20:35
2619
Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC
CHENGDU, China, Aug. 19, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with PD-L1 monocl...
2025-08-19 20:09
1884
Nilesh Shah joins Illumina as Head of Region, AMEA
SINGAPORE, Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global
leader in DNA sequencing and array-based technologies, announced today the
appointment ofNilesh Shah as Head of Region, AMEA, effective immediately.
2025-08-19 14:14
2355
Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic ma...
2025-08-19 13:26
2059
Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease
* Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real world.[1] * In the recent HARMONIE trial findings, Beyfortus reduced RSV hospitalisation...
2025-08-19 11:00
2885
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary o...
2025-08-19 08:00
2338
Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).
* This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted. * DXVX is taking the lead in business development, with several companies in the due diligence stage, and additional deals are anticipated. SEOUL, South...
2025-08-18 21:00
2186
LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious d...
2025-08-18 20:00
3078
KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
* Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion * Research and development expenses was approximately RMB611.5 million * Loss for the period was RMB145.2 million; adjusted loss for the period[1] ...
2025-08-18 18:29
2704
GC Biopharma Signs MOU with Thai Red Cross Society to Strengthen Collaboration on Plasma-Derived Therapies
YONGIN, South Korea, Aug. 18, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a Memorandum of Understanding (MOU) with the Thai Red Cross Society (TRCS) to cooperate on workforce training for the production of plasma-deri...
2025-08-18 12:40
2218
Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity
- Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting bothGLP-1 receptor (GLP-1R) and GIP receptor (GIPR), resulted in a 44.8% reduction in body weight after 14 days of treatment in a diet-induced obese (DIO) mouse model. - Combination of a low dose of ASC47 with A...
2025-08-18 08:15
1994
Week's Top Stories
Most Reposted
Agoda Establishes Strategic Partnership with Taipei City Government, Promoting International Tourism Development
[Picked up by 312 media titles]
2026-04-16 17:15
Hai Robotics and Maersk Redefine Fashion Fulfilment with High-Density Robotics at 10-Metre Scale in Singapore
[Picked up by 298 media titles]
2026-04-14 10:00
Blaize and Winmate Announce Strategic Collaboration to Advance Sovereign Edge AI Capabilities for Defense and Critical Infrastructure
[Picked up by 296 media titles]
2026-04-16 18:00
One Bangkok Hosted "Sunsational Songkran Festival 2026"
[Picked up by 289 media titles]
2026-04-16 15:34
Silicon Box Announces It Joins Imec Automotive Chiplet Program to Strengthen Chip Supply Chains for Next-Generation Vehicles
[Picked up by 288 media titles]
2026-04-15 21:02
Most Read
NYSE Content Update: Sourcery Founder Molly O'Shea Joins as a Media Partner
2026-04-10 21:14
8203
High Templar Tech Limited Files Its Annual Report on Form 20-F
2026-04-10 18:30
8136